Mitral heart valve regurgitation (MR) is one of the most common reasons for cardiac failure. The current gold standard therapy is surgical repair by open heart surgery at the arrested heart. CoreMedic is developing ChordArt^(TM), a novel heart valve repair system that is less invasive, easy to use and most importantly, will result in an excellent outcome for the patient. This therapy will allow the treatment of millions of patients suffering from this disease.
 

The goal of CoreMedic's novel medical device is to improve the treatment for patients with mitral heart valve regurgitation. With its minimally invasive approach, ChordArt^(TM) allows the treatment of patients that are currently excluded from the therapy due to the invasiveness of today's gold standard, the surgical repair.
 

CoreMedic will use the raised capital to further develop its ChordArt^(TM) technologies. A first in human clinical use will be advanced for 2018 as well as the initiation of a clinical trial that will support the European approval (CE) of the product.
 

"Our novel ChordArt^(TM) repair concept offers tremendous advantages compared to the currently applied open heart surgery at arrested heart. Due to the significantly reduced invasiveness, the ChordArt^(TM) approach has not only the potential to allow treatment of currently untreatable patients. It can also reduce the trauma of patients that undergo treatment with today's gold standard substantially", says Thomas Bauer, CEO of CoreMedic.
 

"The implant to repair the malfunction of the mitral valve has a minimal footprint and is truly respecting the natural anatomy of the heart. Therefore it is not 'burning any bridges' for follow-up treatments that might be required later and is leaving the physician and the patients options that no other device is offering right now", he continues.
 

Hubertus Leonhardt, Managing Partner at SHS comments: "Proven results of pre-clinical studies have shown that CoreMedic's ChordArt^(TM) incorporates the potential to have an enormous impact on the treatment of structural heart diseases. We are looking forward to supporting CoreMedic on their path to demonstrate the superiority of the ChordArt^(TM) system in clinical application and to further develop this novel device. We can provide CoreMedic both capital and our industry expertise with an extensive network and over 20 years of experience in the medical technology and life-science sector."
 

With a total volume of 125 million euro, the fourth SHS fund is focusing on expansion financing, changes in shareholder structures and successor situations. The Tuebingen based investor is planning further acquisitions and investments in the fast-growing medical technology and life-science industries in Germany, Austria and Switzerland in the months ahead.
 

About CoreMedic:

CoreMedic has been founded in 2012 in Bern, Switzerland and is a privately help medical device company with locations in Biel, Switzerland and Tuebingen, Germany.

CoreMedic emerged out of the clinical environment directly addressing unmet clinical needs of physicians and surgeons.

CoreMedic is focusing on the development of devices and therapies to address the treatment of heart valve diseases which is representing a multi-billion dollar market globally.

CoreMedic's ChordArt^(TM) mitral valve repair system is focusing on the minimally invasive, trans-femoral repair at the beating heart.

CoreMedic consists of a team of skilled and dedicated professionals with a diverse background in medical application (surgeons and cardiologists), management, research and development, regulatory and quality assurance. The team has a proven track record setting up and managing innovative medical device companies, and has developed an extensive network of contacts over many years including internationally renowned surgeons, physicians and opinion leaders in the field of cardiovascular therapies.

CoreMedic is EN ISO 13485:2012 certified.

Further information, visit www.coremedic.ch
 

About SHS Gesellschaft für Beteiligungsmanagement mbH

SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. SHS was founded in 1993 and has since gained extensive experience as industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund's German and international investors include about the European Investment Fund, professional pension insurers, retirement funds, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company is currently investing from its fourth generation of funds, for which investors have provided 125 million euro. Equity of up to 20 million euro is invested. Transactions can be carried out in the mid double-digit million range together with a network of co-investors. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners at SHS.

Further information: www.shs-capital.eu

Are you interested in receiving regular updates about SHS? Subscribe to our newsletter! http://www.shs-capital.eu/newsletter/
 

PR Contact:

Dr. Reinhard Saller
Ira Wülfing Kommunikation GmbH
Tel.: +49 (0) 89 2000 3038
Fax: +49 (0) 89 2000 3040
reinhard.saller@wuelfing-kommunikation.de
www.wuelfing-kommunikation.de